



IPW

In re Application of: Michele CARGILL, et al.

Art Unit: 1645

Serial No.: 10/767,471

Examiner: TBA

Filed: January 30, 2004

Atty. Docket: CL001505

For: GENETIC POLYMORPHISMS ASSOCIATED  
WITH RHEUMATOID ARTHRITIS, METHODS OF  
DETECTION AND USES THEREOF

**Statement Regarding Duty to Disclose Information Material To Patentability Under  
37 CFR 1.56 (a) and (b)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

No fee is due for this submission. However, the Patent and Trademark Office is authorized to charge any necessary fees related to the processing of this application to Deposit Account No. 50-0970.

Respectfully submitted,


CELERA GENOMICS

Date: October 28, 2004

By: 

Justin D. Karjala, Reg No. 43,704

Celera Genomics  
45 West Gude Drive, C1-1#316  
Rockville, MD 20850  
Tel: 240-453-3812  
Fax: 240-453-3084



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449 PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

### Complete if Known

Application Number	10/767,471
Filing Date	January 30, 2004
First Named Inventor	Michele CARGILL, et al.
Art Unit	1645
Examiner Name	TBA
Attorney Docket Number	CL001505

### U.S. PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

### FOREIGN PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		WO 01/11084 A	02-15-2001	KIMBERLY, R. P., et al.		
		WO 02/074989 A	09-26-2002	GOUGH, S., et al.		


Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO		<b>Complete if Known</b>	
		Application Number	10/767,471
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Filing Date	January 30, 2004
		First Named Inventor	Michele CARGILL, et al.
		Group Art Unit	1645
		Examiner Name	TBA
		Attorney Docket Number	CL001505
Sheet	2	of	3

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Database Genbank Retrieved on 12.07.04 6 July 2000, "Human DNA Sequence from Clone RP11-179A5 on Chromosome 1" Database Accession No. AL365225	
		MORGAN, Ann W. et al., "Fcgamma Receptor Type IIIA is associated with Rheumatoid Arthritis in Two Distinct Ethnic Groups", Arthritis and Rheumatism, vol. 43, no. 10, October 2000, pages 2328-2334	
		WALDON-LYNCH F. et al., "Tumour Necrosis Factor 5' Promoter Single Nucleotide Polymorphisms Influence Susceptibility to Rheumatoid Arthritis (RA) in Immunogenetically Defined Multiplex RA Families", Genes and Immunity, April 2001, Pages 82-87	
		YAMADA, R. et al., "Association between a Single-Nucleotide Polymorphism in the Promoter of the Human Interleukin-3 Gene and Rheumatoid Arthritis in Japanese Patients and Maximum-Likelihood Estimation of Effect that Two Genetic Loci Have on Susceptibility to the Diseases", American Journal of Human Genetics, American Society of Human Genetics, Chicago, IL, U.S., vol. 68, no. 3, 2001, pages 674-685	
		Copy of International Search Report dated October 19, 2004	
		Copy of Written Opinion dated October 19, 2004	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

